{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:58:12Z","timestamp":1792760292900,"version":"4.5.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.ygyno.2014.11.005","type":"journal-article","created":{"date-parts":[[2014,11,8]],"date-time":"2014-11-08T18:03:05Z","timestamp":1415469785000},"page":"25-29","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"title":["The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer"],"prefix":"10.1016","volume":"136","author":[{"given":"Erin K.","family":"Crane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte C.","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro T.","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen M.","family":"Schmeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anais","family":"Malpica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Gershenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ygyno.2014.11.005_bb0005","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3322\/caac.21166","article-title":"Cancer statistics, 2013","volume":"63","author":"Siegel","year":"2013","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"10.1016\/j.ygyno.2014.11.005_bb0010","doi-asserted-by":"crossref","first-page":"459.e1","DOI":"10.1016\/j.ajog.2008.01.035","article-title":"Epidemiology of low-grade serous ovarian cancer","volume":"198","author":"Plaxe","year":"2008","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.ygyno.2014.11.005_bb0015","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/01.pgp.0000101080.35393.16","article-title":"The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin","volume":"23","author":"Seidman","year":"2004","journal-title":"Int J Gynecol Pathol"},{"issue":"2","key":"10.1016\/j.ygyno.2014.11.005_bb0020","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/01.AOG.0000227787.24587.d1","article-title":"Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary","volume":"108","author":"Gershenson","year":"2006","journal-title":"Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.ygyno.2014.11.005_bb0025","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.ygyno.2007.01.030","article-title":"Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma","volume":"105","author":"Shvartsman","year":"2007","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.ygyno.2014.11.005_bb0030","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/S0002-9440(10)62549-7","article-title":"Diverse tumorigenic pathways in ovarian serous carcinoma","volume":"160","author":"Singer","year":"2002","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ygyno.2014.11.005_bb0035","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1200\/EdBook_AM.2013.33.e195","article-title":"The life and times of low-grade serous carcinoma of the ovary","volume":"2013","author":"Gershenson","year":"2013","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"2 Pt 1","key":"10.1016\/j.ygyno.2014.11.005_bb0040","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/AOG.0b013e31829ce7ec","article-title":"Survival in women with grade 1 serous ovarian carcinoma","volume":"122","author":"Fader","year":"2013","journal-title":"Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.ygyno.2014.11.005_bb0045","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ygyno.2009.03.001","article-title":"Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant","volume":"114","author":"Gershenson","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ygyno.2014.11.005_bb0050","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ygyno.2007.11.013","article-title":"Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum","volume":"108","author":"Schmeler","year":"2008","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ygyno.2014.11.005_bb0055","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S1470-2045(12)70572-7","article-title":"Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study","volume":"14","author":"Farley","year":"2013","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ygyno.2014.11.005_bb0060","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ygyno.2008.08.033","article-title":"Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis","volume":"112","author":"Bristow","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2014.11.005_bb0065","first-page":"CD008765","article-title":"Surgical cytoreduction for recurrent epithelial ovarian cancer","volume":"2","author":"Al Rawahi","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"10.1016\/j.ygyno.2014.11.005_bb0075","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/bjc.2011.328","article-title":"Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort","volume":"105","author":"Zang","year":"2011","journal-title":"Br J Cancer"},{"issue":"12","key":"10.1016\/j.ygyno.2014.11.005_bb0080","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1245\/s10434-006-9058-0","article-title":"Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial","volume":"13","author":"Harter","year":"2006","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.ygyno.2014.11.005_bb0085","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1245\/s10434-011-1873-2","article-title":"A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection","volume":"19","author":"Tian","year":"2012","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10.1016\/j.ygyno.2014.11.005_bb0090","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/jso.21470","article-title":"Secondary cytoreductive surgery in the management of platinum-sensitive recurrent epithelial ovarian cancer","volume":"101","author":"Park","year":"2010","journal-title":"J Surg Oncol"},{"issue":"2","key":"10.1016\/j.ygyno.2014.11.005_bb0095","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3802\/jgo.2009.20.2.101","article-title":"Prognostic factors of secondary cytoreductive surgery for patients with recurrent epithelial ovarian cancer","volume":"20","author":"Bae","year":"2009","journal-title":"J Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.ygyno.2014.11.005_bb0100","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/cncr.22447","article-title":"Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome","volume":"109","author":"Salani","year":"2007","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.ygyno.2014.11.005_bb0105","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1097\/IGC.0b013e31821743f9","article-title":"Preoperative factors predicting survival after secondary cytoreduction for recurrent ovarian cancer","volume":"21","author":"Frederick","year":"2011","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2014.11.005_bb0110","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0029-7844(01)01649-0","article-title":"Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential","volume":"99","author":"Crispens","year":"2002","journal-title":"Obstet Gynecol"},{"issue":"4","key":"10.1016\/j.ygyno.2014.11.005_bb0115","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/cncr.10789","article-title":"Recurrent micropapillary serous ovarian carcinoma","volume":"95","author":"Bristow","year":"2002","journal-title":"Cancer"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825814014188?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825814014188?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T17:49:57Z","timestamp":1717523397000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825814014188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S0090825814014188"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2014.11.005","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2014.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}